Analystreport

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $30.00 price target on the stock.

Aclaris Therapeutics, Inc.  (ACRS) 
Last aclaris therapeutics, inc. earnings: 2/25 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: aclaristx.com